Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial

Moss, Penny; Benson, Heather A. E.; Will, R.; Wright, Anthony

doi:10.1016/j.joca.2017.07.009

Cited by 25 publications

(23 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…«Центральные» эффекты эторикоксиба, связанные с его способностью проникать через ГЭБ, продемонстрированы как минимум в двух клинических исследованиях [31,32]. Так, P. Moss и соавт.…”

Section: п р и м е н е н и е э т о р и к о к с и б аunclassified

“…Так, P. Moss и соавт. [32] с помощью тестов для оценки невропатической боли и гипералгезии сравнивали обезболивающее действие эторикоксиба и плацебо у 80 пациентов с ОА коленного сустава. Согласно полученным данным, через 2 нед приема эторикоксиба выраженность боли по индексу WOMAС снизилась на 32,2%.…”

Section: п р и м е н е н и е э т о р и к о к с и б аunclassified

See 1 more Smart Citation

Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug

Каратеев¹

2020

RJTAO

View full text Add to dashboard Cite

Section: п р и м е н е н и е э т о р и к о к с и б аunclassified

Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug

Каратеев¹

2020

RJTAO

View full text Add to dashboard Cite

“…Physical function was assessed at baseline and at the end of the 48 h study period using the three tasks of the Aggregated Locomotor Function Score (ALF) [2,18] in standardized order. The time taken to complete the three tasks was measured using a stop watch: stand-to-sit-to-stand (walk two metres to a chair, sit, stand, and return); eight metre return walk; and, stairs (14 step ascent and descent).…”

Section: Physical Function Testsmentioning

confidence: 99%

“…Here, we demonstrate how a well-defined set of clinical testing protocols and an efficient clinical trial design can be utilized to demonstrate short term clinical efficacy to achieve proof of concept and facilitate the pharmaceutical product design process in the development of transdermal delivery systems for pain management. We have developed a clinical testing toolkit [2] and short term trial design that allows for the assessment of both pain and function in patients with knee osteoarthritis (OA). This paper describes the toolkit's application in a short-term, crossover trial to evaluate the key clinical parameters for a novel transdermal patch that delivered a non-steroidal anti-inflammatory drug (NSAID) to painful osteoarthritic knees.…”

Section: Introductionmentioning

confidence: 99%

Monitoring the Clinical Response to an Innovative Transdermal Delivery System for Ibuprofen

et al. 2019

View full text Add to dashboard Cite

We present a phase 1 study that utilizes a crossover design that provides a rapid and relatively inexpensive methodology for evaluating a new transdermal product. The treatment for osteoarthritis (OA) aims to reduce pain and improve function. An innovative magnetophoresis technology has been developed that facilitates transdermal delivery of ibuprofen. The study used measures that were taken over a relatively short time period to monitor the pharmacodynamic response to ibuprofen. Each participant received magnetophoresis-enhanced transdermal ibuprofen or placebo in randomised order, with a five-day washout period. The participants were 24 volunteers with medically diagnosed, painful knee OA. The primary outcome measures were VAS rating of pain on movement and Western Ontario and McMaster Universities (WOMAC) pain and function scores. VAS for pain on movement (p < 0.001), WOMAC pain score (p = 0.004), and WOMAC function score (p = 0.004) were all significantly improved. There was a significant reduction in movement-related pain (p < 0.05) during the first patch application and for the remainder of the study period. The number needed to treat for a 50% reduction in movement related pain was 2.2. The study showed a rapid and significant analgesic effect in response to transdermal ibuprofen. A short trial of this nature can be used for informing the parameters that are required for a major randomised controlled trial.

show abstract

“…ibuprofen, ketoprofen, diclofenac [8]. Etoricoxib is a COX-2 speci c NSAID that is orally administered [12] and well-established as a therapy for arthritic conditions including osteoarthritis of the knee [13,14], hip [14] and rheumatoid arthritis [15]. Etoricoxib has also been shown to be an effective analgesic for acute postoperative pain [16], chronic low back pain [17], gout [18], ankylosing spondylitis [19,20] and other pain conditions [21].…”

Section: Introductionmentioning

confidence: 99%

Pulsed Shortwave Therapy in Cervical Osteoarthritis: An NSAID- Controlled, Randomized Clinical Trial

Mohameed¹,

Koneru

Staelin

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective Assess treatment superiority of Pulsed Shortwave Therapy (PSWT) against COX-2 NSAID therapy, in reducing disability and pain due to cervical osteoarthritis.Design 200chronic pain suffers (average pain duration about 2 years)diagnosed with cervical osteoarthritis by radiological imaging were randomized into one of two treatmentarms: COX-2 NSAID treatment: Etoricoxib 60mg/day for 4 weeks; or, PSWT treatmentworn 24 hours/day for 4 weeks. The primary outcome measure was the 4-week score on the Neck Disability Index (NDI): a 10-question assessment on a 50-point scale. Secondary outcome measures included pain(at rest and during activity)measured on a Visual Analog Scale (VAS)of0-100 mm, dose count of rescue pain medication (paracetamol)use and a treatment satisfaction rating. These 4-week scores were compared across the two arms to assess superiority.Results After 4 weeks of treatment,subjects in both study arms reported significantly lower (p<0.0001) 4-week measures (11.24-NSAID;9.34-PSWT; 0-50 points),VASrest (30.08-NSAID;22.76-PSWT; 0-100 mm) and VASactivity (36.40-NSAID; 27.42-PSWT; 0-100 mm).The absolute reduction from baseline in NDI was significantly greater in the PSWT arm than NSAID arm(by 3.66 points; 95% CI 2.3 to 5.02; p<0.0001). Similarly, the reductions from baseline inVASrest and VASactivitywere significantly greater in the PSWT arm than NSAID arm(by 10.89 mm;95% CI 6.90 to 14.87; p<0.0001 and 12.05 mm;95% CI 7.76 to 16.33; p<0.0001 respectively).The PSWT arm used 50% less rescue pain medication. Eleven adverse effects were reported in the NSAID arm and zero in the PSWT arm.Conclusion Both NSAID and PSWT treatments resulted in clinically meaningful increases in quality of life(NDI) and decreases in pain (VAS) associated with cervicalosteoarthritis. However, the PSWT armshowed superior improvements in all outcome measures when compared to the NSAID armwith no adverse effects.

show abstract

Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial

Abstract: Just 14 days of etoricoxib significantly improves pain intensity and quality, function and local and widespread hyperalgesia, measured by both self-report and physical tests.

Cited by 25 publications

References 36 publications

Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug

Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug

Monitoring the Clinical Response to an Innovative Transdermal Delivery System for Ibuprofen

Pulsed Shortwave Therapy in Cervical Osteoarthritis: An NSAID- Controlled, Randomized Clinical Trial

Contact Info

Product

Resources

About